Stock Events

Stock Events

Traws Pharma 

$2.18
116
+$0.48+28.24% Friday 20:10

Statistics

Day High
2.4
Day Low
1.79
52W High
3.13
52W Low
1.09
Volume
89,123,300
Avg. Volume
-
Mkt Cap
17.42M
P/E Ratio
1.82
Dividend Yield
-
Dividend
-

Upcoming

Earnings

18MayExpected
Q1 2024
Q2 2024
Q3 2024
Q1 2025
Q2 2025
Q3 2025
Next
-121.75
-80.47
-39.19
2.09
Expected EPS
-0.5608
Actual EPS
N/A

Financials

-73,682.74%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
452,000Revenue
-333.05MNet Income

Analyst Ratings

8Average Price Target
The highest estimate is 8.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow TRAW. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap163.4B
Gilead Sciences is a biopharmaceutical company that develops drugs for cancer, a direct competition to Onconova's focus on cancer therapeutics.
AMGEN
AMGN
Mkt Cap178B
Amgen focuses on human therapeutics, including treatments for cancer, making it a competitor in the oncology space.
Bristol-Myers Squibb
BMY
Mkt Cap118.87B
Bristol Myers Squibb is involved in discovering, developing, and delivering innovative medicines for cancer, directly competing with Onconova's cancer therapy research.
Pfizer
PFE
Mkt Cap149.77B
Pfizer develops and produces medicines and vaccines for a wide range of medical disciplines, including oncology, competing in the cancer treatment market.
Merck
MRK
Mkt Cap277.02B
Merck is known for its cancer drugs and vaccines, making it a competitor in the oncology sector.
Novartis
NVS
Mkt Cap279.67B
Novartis focuses on patented medicines for a range of diseases, including cancer, competing with Onconova's therapeutic developments.
Abbvie
ABBV
Mkt Cap365.43B
AbbVie operates in the pharmaceuticals sector, focusing on oncology, among other areas, making it a competitor.
Astrazeneca
AZN
Mkt Cap286.4B
AstraZeneca operates in the biopharmaceutical sector, focusing on the development of cancer drugs, directly competing with Onconova.
Lilly(Eli) &
LLY
Mkt Cap862.01B
Eli Lilly and Company develops a wide range of pharmaceutical products, including cancer treatments, making it a competitor.
Regeneron Pharmaceuticals
REGN
Mkt Cap73.54B
Regeneron Pharmaceuticals focuses on developing medicines for serious medical conditions, including cancer, competing in the same space as Onconova.

About

Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.
Show more...
CEO
Dr. Victor Mandia Moyo M.D.
Employees
6
Country
United States
ISIN
US68232V8845

Listings

F
DE
0T20.F
STU
DE
0T20.STU
MU
DE
0T20.MU
XNAS
US
TRAW

0 Comments

Share your thoughts

FAQ

What is Traws Pharma stock price today?▼
The current price of TRAW is $2.18 USD — it has increased by +28.24% in the past 24 hours. Watch Traws Pharma stock price performance more closely on the chart.
What is Traws Pharma stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Traws Pharma stocks are traded under the ticker TRAW.
Is Traws Pharma stock price growing?▼
TRAW stock has risen by +46.31% compared to the previous week, the month change is a +47.3% rise, over the last year Traws Pharma has showed a +63.91% increase.
What is Traws Pharma market cap?▼
Today Traws Pharma has the market capitalization of 17.42M
When is the next Traws Pharma earnings date?▼
Traws Pharma is going to release the next earnings report on May 18, 2026.
What were Traws Pharma earnings last quarter?▼
TRAW earnings for the last quarter are -0.34 USD per share, whereas the estimation was -9.16 USD resulting in a +96.29% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Traws Pharma revenue for the last year?▼
Traws Pharma revenue for the last year amounts to 452,000 USD.
What is Traws Pharma net income for the last year?▼
TRAW net income for the last year is -333.05M USD.
How many employees does Traws Pharma have?▼
As of May 10, 2026, the company has 6 employees.
In which sector is Traws Pharma located?▼
Traws Pharma operates in the Health & Wellness sector.
When did Traws Pharma complete a stock split?▼
The last stock split for Traws Pharma was on September 23, 2024 with a ratio of 1:25.
Where is Traws Pharma headquartered?▼
Traws Pharma is headquartered in Newtown, United States.